Tuesday, November 26, 2019

Palo Alto Networks set to acquire Aporeto for US$150 million; boosts its cloud security lineup

Palo Alto Networks has announced that it has entered into a definitive agreement to acquire Aporeto Inc., a machine identity-based microsegmentation company.

Under the terms of the agreement, Palo Alto Networks will pay approximately $150 million in cash to acquire Aporeto, subject to customary adjustments. The acquisition is expected to close during Palo Alto Networks fiscal second quarter, subject to the satisfaction of customary closing conditions.


Palo Alto Networks provides complete cloud security suite in the industry, with a broad set of capabilities in all critical areas of cloud security. The proposed acquisition of Aporeto will further strengthen the company’s Cloud Native Security Platform delivered by Prisma Cloud.

Aporeto identifies workloads and applies microsegmentation across all infrastructures, helping customers secure their applications at scale. Dimitri Stiliadis and Satyam Sinha have agreed to join Palo Alto Networks.

"We are thrilled to welcome Aporeto to the Palo Alto Networks family. We believe the addition of Aporeto’s unique machine identity technology will further enhance our leading Prisma Cloud capabilities and strengthen our commitment to helping customers secure their journey to the cloud,” said Nikesh Arora, chairman and CEO, Palo Alto Networks.


"We have dedicated ourselves to helping organizations securely embrace the cloud,” said Dimitri Stiliadis, co-founder and CTO, Aporeto. “Teaming up with Palo Alto Networks allows us to bring our machine identity-based microsegmentation technology to a large customer base. We are thrilled to join forces to help customers secure their journey to the cloud."

No comments:

Post a Comment

Masimo secures FDA clearance for neonatal RD SET Pulse Oximetry sensors with improved accuracy specifications

Masimo announced that RD SET sensors with Masimo Measure-through Motion and Low Perfusion SET pulse oximetry have received FDA clearance ...